Business Context and Reporting Period
This Form 8-K filing by 20/20 Biolabs, Inc. (Nasdaq: AIDX) reports on the results of an adjourned annual meeting of stockholders held on September 16, 2026. The report was filed on September 18, 2026. The meeting was convened to vote on a previously failed proposal to amend the company's charter.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial performance data. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material event reported is the successful approval of a charter amendment following an adjournment from the August 18, 2026, annual meeting. Key details include:
- Proposal 3 Approval: Stockholders approved an amendment to increase the authorized common stock from 50 million shares to 500 million shares.
- Voting Results:
- Votes For: 3,028,609
- Votes Against: 1,155,607
- Abstentions: 72,621
- Quorum: 4,256,837 shares were represented at the meeting, constituting a quorum out of 12,251,198 shares outstanding as of the record date (June 22, 2026).
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, or specific risk factors beyond the context of the shareholder vote. The approval of the charter amendment removes the immediate contingency of the failed proposal from the prior meeting.
Investor Verification Checklist
- Verify the effective date of the charter amendment with the Delaware Secretary of State.
- Review the definitive proxy statement dated June 23, 2026, for the full rationale behind the 10x increase in authorized shares.
- Monitor subsequent filings for any immediate issuance of shares from the newly authorized pool.
- Confirm the current share count and dilution impact in the next quarterly report (10-Q).